These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10168034)

  • 1. Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy.
    Obenchain RL; Melfi CA; Croghan TW; Buesching DP
    Pharmacoeconomics; 1997 May; 11(5):464-72. PubMed ID: 10168034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness inferences from bootstrap quadrant confidence levels: three degrees of dominance.
    Obenchain RL; Robinson RL; Swindle RW
    J Biopharm Stat; 2005; 15(3):419-36. PubMed ID: 15920889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial.
    Sacristán JA; Gilaberte I; Boto B; Buesching DP; Obenchain RL; Demitrack M; Pérez Sola V; Alvarez E; Artigas F
    Int Clin Psychopharmacol; 2000 Mar; 15(2):107-13. PubMed ID: 10759342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis.
    Sclar DA; Skaer TL; Robison LM; Galin RS; Legg RF; Nemec NL
    J Clin Psychiatry; 1998; 59 Suppl 2():13-7. PubMed ID: 9559755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization.
    Sclar DA; Robison LM; Skaer TL; Galin RS; Legg RF; Nemec NL; Hughes TE; Buesching DP; Morgan M
    J Int Med Res; 1995; 23(6):395-412. PubMed ID: 8746607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of a treatment advice to discontinue inappropriate long-term antidepressant use in primary care.
    Eveleigh R; Grutters J; Muskens E; Oude Voshaar R; van Weel C; Speckens A; Lucassen P
    Fam Pract; 2014 Oct; 31(5):578-84. PubMed ID: 25121977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the rapid response of an antidepressant contribute to better cost-effectiveness? Comparison between mirtazapine and SSRIs for first-line treatment of depression in Japan.
    Sado M; Wada M; Ninomiya A; Nohara H; Kosugi T; Arai M; Endo R; Mimura M
    Psychiatry Clin Neurosci; 2019 Jul; 73(7):400-408. PubMed ID: 30973181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the cost effectiveness of antidepressant treatment in primary care.
    Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
    Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antidepressant therapy on health care utilization and costs in primary care.
    Croghan TW; Lair TJ; Engelhart L; Crown WE; Copley-Merriman C; Melfi CA; Obenchain RL; Buesching DP
    Psychiatr Serv; 1997 Nov; 48(11):1420-6. PubMed ID: 9355169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
    Simpson KN; Welch MJ; Kozel FA; Demitrack MA; Nahas Z
    Adv Ther; 2009 Mar; 26(3):346-68. PubMed ID: 19330495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan.
    Sado M; Knapp M; Yamauchi K; Fujisawa D; So M; Nakagawa A; Kikuchi T; Ono Y
    Aust N Z J Psychiatry; 2009 Jun; 43(6):539-47. PubMed ID: 19440886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant selection and use and healthcare expenditures. An empirical approach.
    Crown WH; Hylan TR; Meneades L
    Pharmacoeconomics; 1998 Apr; 13(4):435-48. PubMed ID: 10178667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
    Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants.
    Bosmans JE; Brook OH; van Hout HP; de Bruijne MC; Nieuwenhuyse H; Bouter LM; Stalman WA; van Tulder MW
    Pharmacoeconomics; 2007; 25(1):25-37. PubMed ID: 17192116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
    Nguyen KH; Gordon LG
    Value Health; 2015 Jul; 18(5):597-604. PubMed ID: 26297087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact of nonpersistence with antidepressant treatment in the adult population of Quebec: a comparative cost-effectiveness approach.
    Béland SG; Tournier M; Galbaud du Fort G; Crott R; Ducruet T; Pariente A; Moride Y
    Value Health; 2011 Jun; 14(4):492-8. PubMed ID: 21669374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
    J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental cost-effectiveness of adult spinal deformity surgery: observed quality-adjusted life years with surgery compared with predicted quality-adjusted life years without surgery.
    McCarthy I; O'Brien M; Ames C; Robinson C; Errico T; Polly DW; Hostin R;
    Neurosurg Focus; 2014 May; 36(5):E3. PubMed ID: 24785485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.